CMAUP Plant Collective Molecular Activities

Plant Name: Horsfieldia glabra

Taxonomic Information:

Plant ID: NPO23007
Plant Latin Name: Horsfieldia glabra
Taxonomy Genus: Horsfieldia
Taxonomy Family: Myristicaceae

Plant External Links:

NCBI TaxonomyDB: n.a.
Plant-of-the-World-Online: n.a.

Used in Medicines:

Country/Region:

India

Traditional Medicine System:

Indian Folk

Geographical Distribution:

India

Geographical Distribution

See the Plant Occurrence Worldwide with Latitude and Longitude Available

Collective Molecular Activities of the Plant

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins
Small molecule receptor (family A GPCR)	DRD1;
Hydrolase	BCHE; ACHE;
Transcription Factor	HIF1A;
Methyl-lysine/arginine binding protein	SMN1;SMN2;
Unclassified	LMNA;

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:	CYP1A2; CYP2D6; CYP2C19;

Detailed Information of Target Proteins

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID
Cytochrome P450 family 1	CYP1A2	Cytochrome P450 1A2	P05177	CHEMBL3356
Cytochrome P450 family 2	CYP2D6	Cytochrome P450 2D6	P10635	CHEMBL289
Cytochrome P450 family 2	CYP2C19	Cytochrome P450 2C19	P33261	CHEMBL3622
Hydrolase	BCHE	Butyrylcholinesterase	P06276	CHEMBL1914
Hydrolase	ACHE	Acetylcholinesterase	P22303	CHEMBL220
Methyl-lysine/arginine binding protein	SMN1;SMN2	Survival motor neuron protein	Q16637	CHEMBL1293232
Small molecule receptor (family A GPCR)	DRD1	Dopamine D1 receptor	P21728	CHEMBL2056
Transcription Factor	HIF1A	Hypoxia-inducible factor 1 alpha	Q16665	CHEMBL4261
Unclassified	LMNA	Prelamin-A/C	P02545	CHEMBL1293235

Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
BP	GO:0008152; metabolic process	GO:0016098; monoterpenoid metabolic process	1.398E-09	2.663E-05	CYP1A2, CYP2C19, CYP2D6
BP	GO:0008152; metabolic process	GO:0009820; alkaloid metabolic process	2.446E-09	2.663E-05	BCHE, CYP1A2, CYP2D6
BP	GO:0008152; metabolic process	GO:0042737; drug catabolic process	1.417E-07	6.172E-04	ACHE, CYP1A2, CYP2C19, CYP2D6
BP	GO:0008152; metabolic process	GO:0006805; xenobiotic metabolic process	1.417E-07	6.172E-04	BCHE, CYP1A2, CYP2C19, CYP2D6
MF	GO:0003824; catalytic activity	GO:0003990; acetylcholinesterase activity	1.930E-07	7.004E-04	ACHE, BCHE
MF	GO:0005488; binding	GO:0019825; oxygen binding	9.828E-07	2.675E-03	CYP1A2, CYP2C19, CYP2D6
BP	GO:0023052; signaling	GO:0050805; negative regulation of synaptic transmission	2.873E-06	6.256E-03	ACHE, BCHE, DRD1
BP	GO:0008152; metabolic process	GO:0097267; omega-hydroxylase P450 pathway	8.667E-06	1.537E-02	CYP1A2, CYP2C19
BP	GO:0008152; metabolic process	GO:0070989; oxidative demethylation	1.271E-05	1.537E-02	CYP1A2, CYP2D6
MF	GO:0003824; catalytic activity	GO:0004497; monooxygenase activity	9.476E-06	1.537E-02	CYP1A2, CYP2C19, CYP2D6
MF	GO:0005488; binding	GO:0020037; heme binding	2.319E-05	2.405E-02	CYP1A2, CYP2C19, CYP2D6
MF	GO:0003824; catalytic activity	GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	4.109E-05	3.437E-02	CYP1A2, CYP2C19, CYP2D6
MF	GO:0005488; binding	GO:0005506; iron ion binding	4.517E-05	3.513E-02	CYP1A2, CYP2C19, CYP2D6
MF	GO:0003824; catalytic activity	GO:0070330; aromatase activity	4.858E-05	3.648E-02	CYP1A2, CYP2D6
CC	GO:0016020; membrane	GO:0005789; endoplasmic reticulum membrane	5.336E-04	1.844E-01	CYP1A2, CYP2C19, CYP2D6, DRD1
CC	GO:0044464; cell part	GO:0005641; nuclear envelope lumen	3.722E-03	5.513E-01	BCHE
CC	GO:0016020; membrane	GO:0031090; organelle membrane	4.210E-03	5.914E-01	CYP1A2, CYP2C19, CYP2D6, DRD1, LMNA
CC	GO:0043226; organelle	GO:0016607; nuclear speck	1.199E-02	8.806E-01	HIF1A, LMNA
CC	GO:0043226; organelle	GO:0097730; non-motile cilium	1.481E-02	9.572E-01	DRD1

Enriched KEGG Pathways of Target Proteins (Activity≤10μM)

Top 10 KEGG Pathways (ordered by adjusted p-value)

Detailed Information of Enriched KEGG Pathways

Pathway Category Top Level	Pathway Category Second Level	Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
09100 Metabolism	09111 Xenobiotics biodegradation and metabolism	hsa00982	Drug metabolism - cytochrome P450	3.253E-06	1.138E-04	CYP2D6, CYP1A2, CYP2C19
09100 Metabolism	09103 Lipid metabolism	hsa00591	Linoleic acid metabolism	7.262E-05	1.271E-03	CYP1A2, CYP2C19
09100 Metabolism	09111 Xenobiotics biodegradation and metabolism	hsa00980	Metabolism of xenobiotics by cytochrome P450	4.653E-04	5.134E-03	CYP2D6, CYP1A2
09150 Organismal Systems	09156 Nervous system	hsa04726	Serotonergic synapse	1.091E-03	7.634E-03	CYP2D6, CYP2C19
09160 Human Diseases	09161 Cancers	hsa05204	Chemical carcinogenesis	5.867E-04	5.134E-03	CYP1A2, CYP2C19
09160 Human Diseases	09164 Substance dependence	hsa05030	Cocaine addiction	2.184E-02	6.911E-02	DRD1
09130 Environmental Information Processing	09132 Signal transduction	hsa04150	mTOR signaling pathway	2.668E-02	6.911E-02	HIF1A
09100 Metabolism	09103 Lipid metabolism	hsa00590	Arachidonic acid metabolism	2.756E-02	6.911E-02	CYP2C19
09160 Human Diseases	09164 Substance dependence	hsa05031	Amphetamine addiction	2.976E-02	6.911E-02	DRD1
09100 Metabolism	09110 Biosynthesis of other secondary metabolites	hsa00232	Caffeine metabolism	2.248E-03	1.311E-02	CYP1A2

Human Diseases Associated with the Target Proteins of the Plant

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Associated Disease Targets (Association Ref: TTD database)
NA: NA	Upper abdominal bloating	NA	ACHE;
A00-B99: Certain infectious and parasitic diseases	Malaria	B54	CYP2D6;
N00-N99: Diseases of the genitourinary system	Urinary dysfunction	N39.3-N39.4	ACHE;
H00-H59: Diseases of the eye and adnexa	Open-angle glaucoma	H40-H42	ACHE;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cocaine addiction	F14.2	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cognitive disorders	F01-F07, F04, F05, R41.3	ACHE; DRD1;
K00-K95: Diseases of the digestive system	Xerostomia	K11.7, R68.2	ACHE;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Dementia	F01-F07	DRD1;
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	ACHE; DRD1;
A00-B99: Certain infectious and parasitic diseases	Pediculus humanus capitis	B85.0	ACHE;
H00-H59: Diseases of the eye and adnexa	Chronic glaucoma	H40-H42	ACHE;
C00-D49: Neoplasms	Cancer	C00-C96	ACHE;
G00-G99: Diseases of the nervous system G00-G99	Parkinson's disease	G20	ACHE; DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychotic disorders	F20-F29	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Substance dependence	F10-F19	DRD1;
NA: NA	Early satiation associated with functional dyspepsia	NA	ACHE;
O00-O9A: Pregnancy, childbirth and the puerperium	Excessive bleeding following childbirth and spontaneous or elective abortion	O04	DRD1;
G00-G99: Diseases of the nervous system G00-G99	Epileptic seizures	G40, P90, R56	ACHE;
S00-T88: Injury, poisoning and certain other consequences of external causes	Poisoning due to pesticides and chemicals	T36-T50	ACHE;
S00-T88: Injury, poisoning and certain other consequences of external causes	Poison intoxication	T36-T50	ACHE;
I00-I99: Diseases of the circulatory system	Hypertension	I10-I16	DRD1;
G00-G99: Diseases of the nervous system G00-G99	Alzheimer disease	G30	ACHE;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Insomnia	F51.0, G47.0	CYP2D6;
H00-H59: Diseases of the eye and adnexa	Glaucoma	H40-H42	ACHE;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychiatric disorder	F01-F99	DRD1;
A00-B99: Certain infectious and parasitic diseases	Helminth infection	A00-B99	ACHE;
G00-G99: Diseases of the nervous system G00-G99	Myasthenia gravis	G70.0	ACHE;
G00-G99: Diseases of the nervous system G00-G99	Myasthenia gravis diagnosis	G70.0	ACHE;
G00-G99: Diseases of the nervous system G00-G99	Neurodegenerative disease	G30-G32	ACHE;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Mild cognitive impairment	F06.7	ACHE;
G00-G99: Diseases of the nervous system G00-G99	Migraine	G43	CYP2D6;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Anxiety disorder	F32, F40-F42	ACHE;
E00-E89: Endocrine, nutritional and metabolic diseases	Type 2 diabetes	E11	DRD1;

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases